Newborn Screening at Scale

Background. Sickle cell disease is a major contributor to avoidable child mortality in sub-Saharan Africa. The Global Burden of Disease Study 2021 attributes 81,100 deaths in children under five to the condition and estimates 376,000 total deaths when excess mortality is included, nearly eleven times the number captured through cause-specific coding alone (GBD 2021 Sickle Cell Disease Collaborators, 2023). In Nigeria, modelling of the 2018 Demographic and Health Survey estimates under-five mortality among affected children at approximately 490 per 1,000 livebirths and attributes about 4.2% of national under-five deaths to excess sickle cell mortality (Nnodu et al., 2021). Most deaths can be prevented through established interventions, including early identification, penicillin prophylaxis, pneumococcal vaccination, parental education and structured follow-up. The challenge is therefore not identifying effective interventions, but delivering them at national scale.

Purpose. This paper proposes a phased implementation model for transitioning newborn screening for sickle cell disease from demonstration projects to national coverage. It is a design paper, not an evaluation. Its central premise is that screening should be treated not as a laboratory service seeking a delivery channel, but as a payload attached to an existing delivery platform with high national coverage.

Approach. The model draws on four evidence streams: cost-effectiveness literature on screening and prophylaxis in sub-Saharan Africa; operational experience from established African screening programmes in Ghana, Uganda, Angola and Tanzania; feasibility evidence on integrating screening into Nigerian immunisation contacts; and the programme architecture of long-running national screening systems, particularly the NHS Sickle Cell and Thalassaemia Screening Programme in England, used for transferable structural lessons rather than wholesale adoption.

Findings. Three design conclusions emerge. First, the principal constraint is not test cost but result-return logistics. Uganda's national programme achieved a cost of US$4.46 per test but a median inbound turnaround time of 16 days; a result received after families have dispersed is effectively a result not delivered (Hernandez et al., 2021). Second, point-of-care immunoassay testing at immunisation contacts can restructure this problem by converting specimen transport into a same-visit clinical encounter. Nigerian feasibility work reported 86% acceptability among mothers attending immunisation clinics (Oluwole et al., 2020). Third, national coverage is more realistically achieved through geographic phasing based on trait prevalence and primary-care readiness than through simultaneous nationwide implementation.

Contribution. The paper proposes a four-phase, eight-year implementation model with defined entry and exit criteria, a costed staffing and consumables envelope, a minimum indicator set, an explicit register of failure modes and mitigations, and a readiness instrument for state-level adoption. It argues that Nigeria's existing National Guideline already provides the core programme architecture; the principal deficit lies in implementation design, financing and accountability rather than policy intent (Federal Ministry of Health, 2022).